Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Background: Current therapy for osteosarcoma pulmonary metastases (PMs) is ineffective. The mechanisms that prevent successful immunotherapy in osteosarcoma are incompletely understood. We investigated the tumor microenvironment of metastatic osteosarcoma with the goal of harnessing the immune system as a therapeutic strategy. Methods: 66 osteosarcoma tissue specimens were analyzed by immunohistochemistry (IHC) and immune markers were digitally quantified. Tumor-infiltrating lymphocytes (TILs) from 25 specimens were profiled by functional cytometry. Comparative transcriptomic studies of distinct tumor-normal lung ‘PM interface’ and ‘PM interior’ regions from 16 PMs were performed. Clinical follow-up (median 24 months) was available from resection. Results: IHC revealed a statistically significantly higher concentration of TILs expressing immune checkpoint and immunoregulatory molecules in PMs compared with primary bone tumors (including programmed cell death 1 (PD-1), programmed death ligand 1 (PD-L1), lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and indoleamine 2,3-dioxygenase (IDO1). Remarkably, these lymphocytes are excluded at the PM interface compared with PM interior. TILs from PMs exhibited significantly higher amounts of PD-1 and LAG-3 and functional cytokines including interferon-γ (IFNγ) by flow cytometry. Gene expression profiling further confirmed the presence of CD8 and CD4 lymphocytes concentrated at the PM interface, along with upregulation of immunoregulatory molecules and IFNγ-driven genes in the same region. We further discovered a strong alternatively activated macrophage signature throughout the entire PMs along with a polymorphonuclear myeloid-derived suppressor cell signature focused at the PM interface. Expression of PD-L1, LAG-3, and colony-stimulating factor 1 receptor (CSF1R) at the PM interface was associated with significantly worse progression-free survival (PFS), while gene sets indicative of productive T cell immune responses (CD8 T cells, T cell survival, and major histocompatibility complex class 1 expression) were associated with significantly improved PFS. Conclusions: Osteosarcoma PMs exhibit immune exclusion characterized by the accumulation of TILs at the PM interface. These TILs produce effector cytokines, suggesting their capability of activation and recognition of tumor antigens. Our findings suggest cooperative immunosuppressive mechanisms in osteosarcoma PMs including immune checkpoint molecule expression and the presence of immunosuppressive myeloid cells. We identify cellular and molecular signatures that are associated with patient outcomes, which could be exploited for successful immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to TIM-3, the expression of LAG-3 and IDO1 are significantly expressed in pulmonary metastatic foci of osteosarcoma and is closely related to immune suppression [33].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674 · cited 1×
“Furthermore, we identified two distinct compartments within the PMs: the immune cell-rich tumor-normal lung ‘interface’ region (PM interface) and the PM interior which was relatively devoid of immune cells (figure 1B).”
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 1×
“J Immunother 2021; 9 :e001772. doi”
Self-citationVisualizing and interpreting cancer genomics data via the Xena platform
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · cited 1×
“J Immunother 2021; 9 :e001772. doi”
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Self-citationIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Self-citationRobbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · cited 1×
“7 13–16 Rigorous understanding of the mechanisms regulating the tumor–immune system interface is a crucial prerequisite for rationally designed therapies to alter the TME in a way that will allow immunotherapy to be effective in osteosarcoma.”
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663
De-novo and acquired resistance to immune checkpoint targeting
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662
Jayasingam, S. D., Citartan, M., Thang, T. H., Mat Zin, A. A., Ang, K. C., & Ch'ng, E. S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01512 · Cited by 635 · cited 1×
“We investigated checkpoint molecules and the corresponding intracellular cytokine expression profile of TILs in osteosarcoma specimens to further characterize functional immune”
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J. S., & Davis, L. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 479
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456
Self-citationInnate immune signaling and regulation in cancer immunotherapy
Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408
Huh, S. J., Liang, S., Sharma, A., Dong, C., & Robertson, G. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4442 · Cited by 352
S100A8/A9 activate key genes and pathways in colon tumor progression
Ichikawa, M., Williams, R., Wang, L., Vogl, T., & Srikrishna, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0394 · Cited by 346
Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0230 · Cited by 329 · cited 1×
“7 13–16 Rigorous understanding of the mechanisms regulating the tumor–immune system interface is a crucial prerequisite for rationally designed therapies to alter the TME in a way that will allow immunotherapy to be effective in osteosarcoma.”
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Immuno-genomic landscape of osteosarcoma
Wu, C.-C., Beird, H. C., Andrew Livingston, J., Advani, S., Mitra, A., Cao, S., Reuben, A., Ingram, D., Wang, W.-L., Ju, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14646-w · Cited by 251
Taube, J. M., Young, G. D., McMiller, T. L., Chen, S., Salas, J. T., Pritchard, T. S., Xu, H., Meeker, A. K., Fan, J., Cheadle, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0244 · Cited by 246
Self-citationChou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245
TIM-3, a promising target for cancer immunotherapy
He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Paoluzzi, L., Cacavio, A., Ghesani, M., Karambelkar, A., Rapkiewicz, A., Weber, J., & Rosen, G. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0064-0 · Cited by 218
The Neutrophil’s Choice: Phagocytose vs Make Neutrophil Extracellular Traps
Manfredi, A. A., Ramirez, G. A., Rovere-Querini, P., & Maugeri, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00288 · Cited by 218
The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma
Beck, A. H., Espinosa, I., Edris, B., Li, R., Montgomery, K., Zhu, S., Varma, S., Marinelli, R. J., van de Rijn, M., & West, R. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1283 · Cited by 210 · cited 2×
“To account for intracorrelations when multiple progressions occurred on the same patient, robust sandwich-type SE estimators were used.”
Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D., Schwab, J., Nielsen, G. P., Chebib, I., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 193
Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190
Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2574 · Cited by 178
Lesokhin, A. M., Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010274 · Cited by 152
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
Wang, D., Niu, X., Wang, Z., Song, C.-L., Huang, Z., Chen, K.-N., Duan, J., Bai, H., Xu, J., Zhao, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1086 · Cited by 150 · cited 1×
“19 20 Nevertheless, a deeper and more granular understanding of the metastatic TME, particularly the precise regional distribution and interplay of immune cells along with the operative immunoregulatory signaling programs, are greatly needed.”
Tsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148
Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?
Jeys, L. M., Grimer, R. J., Carter, S. R., Tillman, R. M., & Abudu, A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9483-8 · Cited by 145
Pignon, J.-C., Jegede, O., Shukla, S. A., Braun, D. A., Horak, C. E., Wind-Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3206 · Cited by 113
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Dancsok, A. R., Setsu, N., Gao, D., Blay, J., Thomas, D. M., Maki, R. G., Nielsen, T. O., & Demicco, E. G. (2019) · Modern Pathology · doi:10.1038/s41379-019-0312-y · Cited by 113
CHEN, Y., XU, S.-F., XU, M., & YU, X.-C. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.528 · Cited by 47
Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
Ge, W., Li, J., Fan, W., Xu, D., & Sun, S. (2017) · Tumor Biology · doi:10.1177/1010428317715643 · Cited by 45
Davis, K. L., Fox, E., Reid, J. M., Liu, X., Minard, C. G., Weigel, B., & Mackall, C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.10526 · Cited by 37
Sorenson, L., Fu, Y., Hood, T., Warren, S. E., & McEachron, T. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629779 · Cited by 21
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Tumor infiltrating lymphocytes (TILs) are mainly distributed in the region expressing human leukocyte antigen Class I, whereas CD4 + and CD8 + T cells concentrated at the pulmonary metastases interface [33].”
BackgroundInfluentialManaging the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 232
“The majority of tumor-infiltrating lymphocytes are clustered at regions overexpressing human leukocyte antigen (HLA) class I in osteosarcomas, while effector T lymphocytes are mostly distributed at the border between healthy tissues and pulmonary metastases.(67,68) Moreover, there are more T lymphocytes in metastases…”
BackgroundPanez-Toro, I., Muñoz-García, J., Vargas-Franco, J. W., Renodon‐Cornière, A., Heymann, M., Lézot, F., & Heymann, D. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00803-9 · Cited by 146
Zhu, T., Han, J., Liu, Y., Cai, Z., Sun, W. Y., Hua, Y., & Xu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907550 · Cited by 134
“In addition to serving as a drug target, the number of MDSCs in the peripheral blood or tumor microenvironment of osteosarcoma is also a promising candidate as a prognostic biomarker (57).”
BackgroundInfluentialImmune checkpoints in osteosarcoma: Recent advances and therapeutic potential
Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 114
Metadata
- Authors
- Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., Morris, C. D., Levin, A., Rhee, D. S., Meyer, C. F., Tam, A. J., Blosser, R., Thompson, E. D., Suru, A., McConkey, D., Housseau, F., Anders, R., Pardoll, D. M., & Llosa, N.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Llosa, Nicolas
- ORCID
- Ligon, John A
- Choi, Woonyoung
- Cojocaru, Gady
- Fu, Wei
- Hsiue, Emily Han-Chung
- Siegel, Nicholas
- Fong, Megan H
- Ladle, Brian
- Pratilas, Christine A
- Morris, Carol D
- Levin, Adam
- Rhee, Daniel S
- Meyer, Christian F
- Tam, Ada J
- Blosser, Richard
- Suru, Aditya
- McConkey, David
- Housseau, Franck
- Anders, Robert
- Pardoll, Drew M
- Llosa, Nicolas
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-05
- Volume
- 9
- Issue
- 5
- Pages
- e001772
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC8144029
- OpenAlex
- W3160748480
- Cited by
- 124
- References
- 52
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 27 · 2023: 26 · 2022: 15 · 2021: 5
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bloomberg Philanthropies
- St. Baldrick’s foundation
- National Pediatric Cancer Foundation
- Giant Food
- Bloomberg-Kimmel Institute for Immunotherapy
- BMS II-ON
- Johns Hopkins Hospital
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune exclusion, tumor-infiltrating lymphocytes, tumor microenvironment, PD-1, PD-L1, LAG-3, TIM-3, IDO1, interferon-gamma, myeloid-derived suppressor cells, M2 macrophages, CSF1R, progression-free survival, immunotherapy resistance, lung metastasis
- MeSH terms
- Myeloid-Derived Suppressor Cells, Progression-Free Survival, Immune Checkpoint Proteins, Tumor-Associated Macrophages, Bone Neoplasms, Humans, Immunotherapy, Lung Neoplasms, Lymphocyte Activation, Macrophage Activation, Retrospective Studies, Osteosarcoma, Biomarkers, Tumor, Cytokines, Lymphocytes, Tumor-Infiltrating, Electronic Health Records, Tumor Microenvironment, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.